Goldman Sachs
CPHR

Goldman Sachs’s Cipher Pharmaceuticals Inc. CPHR Stock Holding History

Goldman Sachs’s Portfolio CPHR Stock Details CPHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-19,430
Closed -$91K – 7521
2015
Q4 		$91K Buy
+19,430
New +$84.1K ﹤0.01% 6234

Other funds holding CPHR

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
TAM
Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
NEI
Northwest & Ethical Investments Toronto, Ontario, Canada $4.32B AUM 23.26% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Goldman Sachs's CPHR Position: Q1 2016 in Review

Goldman Sachs sold out of Cipher Pharmaceuticals Inc. (CPHR) in Q1 2016, closing a stake of 19,430 shares — an estimated $91K sold.

Goldman Sachs first reported a position in CPHR in Q4 2015 and held it in 1 quarter. The position peaked at $91K in Q4 2015. 19 funds tracked by Wall St. Rank hold CPHR as of Q1 2016.

  • Goldman Sachs reported no remaining Cipher Pharmaceuticals Inc. position as of Q1 2016 after selling out during the quarter.
  • Goldman Sachs sold 19,430 Cipher Pharmaceuticals Inc. shares in Q1 2016, an estimated $91K.
  • Goldman Sachs first reported a position in Cipher Pharmaceuticals Inc. in Q4 2015 and held it in 1 quarter.
  • Goldman Sachs's Cipher Pharmaceuticals Inc. position peaked at $91K in Q4 2015.
  • 19 funds tracked by Wall St. Rank held Cipher Pharmaceuticals Inc. as of Q1 2016.

Based on Goldman Sachs's 13F filing for Q1 2016, filed 13 May 2016.